Stéphane A. Laporte


Stéphane A. Laporte, Ph.D.

Division of Endocrinology and Metabolism
Department of Medicine
1001 Decarie Blvd., E02.7210
Montreal, QC, Canada, H4A 3J1

Tel: 514-934-1934 ext. 76186

stephane.laporte [at]

Biographical Sketch

Dr. Laporte received his undergraduate degree in Biology (Major Biotechnology), and M.Sc. and Ph.D. degrees in Pharmacology at the Université de Sherbrooke, Quebec, Canada. He trained as a postdoctoral fellow in the group Dr. Marc G. Caron, at Duke University, USA, before joining McGill in 2001.


G protein-coupled receptor signaling, confocal, BRET, FRET, drugs, cardiovascular diseases, and pre-term birth, cancer.

Research or Clinical Activities

Our laboratory focuses on understanding the molecular and cellular mechanisms regulating G protein-coupled receptors (GPCRs). We are interested in ligand-directed signaling, and the development of novel molecules with allosteric, biased signaling modes of action, in particular for the prostaglandin PG2α (FP) receptor. Using innovative imaging and biophysical approaches we also study the dynamics of protein complexes involved in receptor trafficking and signaling for different GPCRs, including the angiotensin II type 1, bradykinin B2 and glucagon-like peptide 1 (GLP1) receptors. Our laboratory is involved in developing novel fluorescently tagged biosensors for studying, in live cells, GPCR signaling and trafficking, with the goal of identifying small molecules regulator of these responses. Our research program aims at providing new insights into the molecular details of GPCR signaling and trafficking, with the goal of identifying new means to improve hormone and drug efficacy, especially in cardiovascular diseases, inflammation, pre-term birth and cancer.

Selected Recent Publications

Discovery of a dual Ras and ARF6 inhibitor from a GPCR endocytosis screen. Giubilaro J, Schuetz, DA, Namkung Y, Khoury E, Marquez ML, Campbell S, Beautrait A, Armando S, Radresa O, Duchaine J, Lamarche-Vane N, Claing A, Bouvier M, Marinier A, and Laporte SA. Nat. Commun. (2021) Aug 3;12(1):4688. DOI: 10.1038/s41467-021-24968-y

Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors. Namkung Y, LeGouill C, Kumar S, Cao Y, Teixeira LB, Lukasheva V, Giubilaro J, Simões SC, Longpré JM, Devost D, Hébert TE, Piñeyro G, Leduc R, Costa-Neto CM, Bouvier M, Laporte SA. Sci Signal. 2018 Dec 4;11(559). pii: eaat1631. DOI: 10.1126/scisignal.aat1631

A new inhibitor of the β-arrestin/AP2 endocytic complex reveals interplay between GPCR internalization and signalling. Beautrait A, Paradis JS, Zimmerman B, Giubilaro J, Nikolajev L, Armando S, Kobayashi H, Yamani L, Namkung Y, Heydenreich FM, Khoury E, Audet M, Roux PP, Veprintsev DB, Laporte SA, Bouvier M. Nat Commun. 2017 Apr 18;8:15054. DOI: 10.1038/ncomms15054

Monitoring G protein-coupled receptor and β-arrestin trafficking in live cells using enhanced bystander BRET. Namkung Y, Le Gouill C, Lukashova V, Kobayashi H, Hogue M, Khoury E, Song M, Bouvier M, Laporte SA. Nat Commun. 2016 Jul 11;7:12178. DOI: 10.1038/ncomms12178

The conformational signature of β-arrestin2 predicts its trafficking and signalling functions.
Lee MH, Appleton KM, Strungs EG, Kwon JY, Morinelli TA, Peterson YK, Laporte SA, Luttrell LM. Nature. 2016 Mar 31;531(7596):665-8. DOI: 10.1038/nature17154

PubMed Publications – S. Laporte


Back to top